Abstract
SummaryRocuronium is increasingly used as the neuromuscular blocking agent of choice in the ICU due to a favourable side effect profile compared with suxamethonium. However, it potentially causes anaphylaxis with one in every 2499 patient exposures. Reports in anaesthetic literature describe the use of sugammadex as a novel treatment for rocuronium‐induced anaphylaxis, but it is not recommended for routine use. No literature specifically relating to ICU patients exists. We describe a case of severe rocuronium‐induced anaphylaxis on ICU, resistant to conventional therapy and resulting in cardiac arrest, being completely reversed by 200 mg sugammadex.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
